Patents by Inventor Melitta Just
Melitta Just has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8669266Abstract: The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: October 5, 2009Date of Patent: March 11, 2014Assignee: SanofiInventors: Marc Nazare, Gernot Zech, Melitta Just, Tilo Weiss, Gerhard Hessler, Joerg Czech
-
Patent number: 8598179Abstract: The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: June 17, 2010Date of Patent: December 3, 2013Assignee: SanofiInventors: Marc Nazaré, Gernot Zech, Jochen Goerlitzer, Melitta Just, Tilo Weiss, Gerhard Hessler, Werngard Czechtizky, Sven Ruf
-
Patent number: 8426420Abstract: The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: June 17, 2010Date of Patent: April 23, 2013Assignee: SanofiInventors: Marc Nazaré, Gernot Zech, Melitta Just, Tilo Weiss, Gerhard Hessler, Markus Kohlmann
-
Patent number: 7910576Abstract: The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; A; B, D and E have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: GrantFiled: December 16, 2009Date of Patent: March 22, 2011Assignee: Sanofi-AventisInventors: Otmar Klingler, Joerg Czech, Werngard Czechtizky, Tilo Weiss, Melitta Just
-
Publication number: 20110039829Abstract: The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: June 17, 2010Publication date: February 17, 2011Applicant: SANOFI-AVENTISInventors: Marc NAZARÉ, Gernot ZECH, Jochen GOERLITZER, Melitta JUST, Tilo WEISS, Gerhard HESSLER, Werngard CZECHTIZKY, Sven RUF
-
Publication number: 20110021537Abstract: The present invention relates to compounds of the formula I, wherein R1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: June 17, 2010Publication date: January 27, 2011Applicant: SANOFI-AVENTISInventors: Marc Nazaré, Gernot Zech, Melitta Just, Tilo Weiss, Gerhard Hessler, Markus Kohlmann
-
Publication number: 20100226918Abstract: The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; A; B, D and E have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: December 16, 2009Publication date: September 9, 2010Applicant: SANOFI-AVENTISInventors: Otmar KLINGLER, Joerg CZECH, Werngard CZECHTIZKY, Tilo WEISS, Melitta JUST
-
Patent number: 7745443Abstract: The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, E, n, m or o have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases.Type: GrantFiled: April 2, 2007Date of Patent: June 29, 2010Assignees: Sanofi-Aventis Deutschland GmbH, Ajinomoto Co., Inc.Inventors: Otmar Klingler, Melitta Just, Kuniya Sakurai, Naoyuki Fukuchi
-
Publication number: 20100135999Abstract: The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.Type: ApplicationFiled: October 5, 2009Publication date: June 3, 2010Applicant: SANOFI-AVENTISInventors: Marc Nazaré, Gernot ZECH, Melitta JUST, Tilo WEISS, Gerhard HESSLER, Joerg Czech
-
Publication number: 20070173489Abstract: The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, E, n, m or o have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases.Type: ApplicationFiled: April 2, 2007Publication date: July 26, 2007Inventors: Otmar Klingler, Melitta Just, Kuniya Sakurai, Naoyuki Fukuchi
-
Patent number: 7235558Abstract: The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, F, n, m and o have the meanings indicated herein. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb).Type: GrantFiled: June 4, 2003Date of Patent: June 26, 2007Assignees: Sanofi-Aventis Deutschland GmbH, Ajinomoto Co., IncInventors: Otmar Klingler, Melitta Just, Kuniya Sakurai, Naoyuki Fukuchi
-
Publication number: 20040067980Abstract: The present invention relates to compounds of the formula I, 1Type: ApplicationFiled: June 4, 2003Publication date: April 8, 2004Inventors: Otmar Klingler, Melitta Just, Kuniya Sakurai, Naoyuki Fukuchi
-
Patent number: 6191282Abstract: 5-Membered ring heterocycle of the formula I, in which D includes a COOR15, CON(CH3)R15 or CONHR15 radical and R15 includes a 6-24 member bicyclic or tricyclic radical, compositions, preparation and use as inhibitors of thrombocyte aggregation, metastasization of carcinoma cells, binding of osteoclasts to bone surfaces and for the treatment of tromboses.Type: GrantFiled: July 28, 1999Date of Patent: February 20, 2001Assignee: Hoechst Marion RousselInventors: Gerhard Zoller, Otmar Klingler, Bernd Jablonka, Melitta Just, Gerhard Breipohl, Jochen Knolle, Wolfgang Konig, Hans-Ulrich Stilz
-
Patent number: 5981492Abstract: The present invention pertains to 5-ring heterocycles of general formula (I), wherein W, Y, Z, B, D, E and R as well as b, c, d, e, f, g, and h are as indicated in the description; to methods for preparing them, and to their use as inhibitors of platelet aggregation, metastasizing of carcinomatous cells and the attachment of osteoclasts to the bone surface.Type: GrantFiled: July 19, 1996Date of Patent: November 9, 1999Assignee: Hoechst AktiengesellschaftInventors: Gerhard Zoller, Otmar Klingler, Bernd Jablonka, Melitta Just, Gerhard Breipohl, Jochen Knolle, Wolfgang Konig, Hans-Ulrich Stilz
-
Patent number: 5703050Abstract: Urea derivates are disclosed having the formula (I). ##STR1## in which A, B, W, Z, R, R.sup.1, R.sup.2, R.sup.3 and r have the meaning given in the description, as well as a process for preparing the same and their use as inhibitors of thrombocyte aggregation, carcinom cell metastasis and osteoclast binding to bone surface.Type: GrantFiled: January 17, 1996Date of Patent: December 30, 1997Assignee: Hoechst AktiengesellschaftInventors: Otmar Klingler, Gerhard Zoller, Bernd Jablonka, Melitta Just, Gerhard Breipohl, Jochen Knolle, Wolfgang Konig, Hans Ulrich Stilz
-
Patent number: 5686421Abstract: Hydantoin derivatives of the formula I ##STR1## in which n is 3 or 4, R.sup.1 is alkyl or a radical of the formula R'--NH--C.dbd.N--R" with R' and R" being hydrogen or alkyl, and R.sup.2 is hydrogen, --NH--CO--NH.sub.2 and optionally substituted alkyl, and a process for the preparation thereof and the use thereof for inhibiting platelet aggregation, are described.Type: GrantFiled: June 6, 1995Date of Patent: November 11, 1997Assignee: Hoechst AktiengesellschaftInventors: Wolfgang Konig, Melitta Just, Bernd Jablonka
-
Patent number: 5681838Abstract: The present invention relates to novel substituted amino compounds of the formula I:R.sup.1 -(A).sub.a -(B).sub.b -(D).sub.c -(CH.sub.2).sub.m -N(R.sup.2)-(CH.sub.2).sub.n -R.sup.3as defined in the present application, and to a process for preparing such compounds. The invention also includes pharmaceutical compositions containing the present compounds, and the preparation of such compositions. The invention also relates to the use of the present compounds as inhibitors of blood-platelet aggregation, formation of metastases by carcinoma cells, and the binding of osteoclasts to bone surfaces, in the treatment of hosts in need thereof.Type: GrantFiled: July 18, 1995Date of Patent: October 28, 1997Assignee: Hoechst AktiengesellschaftInventors: Gerhard Zoller, Bernd Jablonka, Melitta Just, Otmar Klingler, Gerhard Breipohl, Jochen Knolle, Wolfgang Konig
-
Patent number: 5658935Abstract: The invention concerns heterocyclic compounds of the general formula (I) in which A, B, R, R.sup.2, R.sup.3, W, Y, Z.sup.1, Z.sup.2 and r are as defined in the description, methods of preparing them and their use as inhibitors of thrombocyte aggregation, the metastization of carcinoma cells and the binding of osteoclasts on bone surfaces.Type: GrantFiled: January 17, 1996Date of Patent: August 19, 1997Assignee: Hoechst AktiengesellschaftInventors: Otmar Klingler, Gerhard Zoller, Bernd Jablonka, Melitta Just, Gerhard Breipohl, Jochen Knolle, Wolfgang Konig
-
Patent number: 5554594Abstract: The present invention relates to compounds of the general formula I ##STR1## in which R, R.sup.1 to R.sup.4, r, Y, Z and W are defined as indicated in the description, a process for their preparation and their use as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.Type: GrantFiled: May 31, 1995Date of Patent: September 10, 1996Assignee: Cassella AktiengessellschaftInventors: Gerhard Zoller, Bernd Jablonka, Melitta Just, Otmar Klingler, Gerhard Breipohl, Jochen Knolle, Wolfgang K onig
-
Patent number: 5424293Abstract: Phenylimidazolidine derivatives of the general formula I ##STR1## in which, for example, Y denotes --CH.sub.2 --CH.sub.2 --CO--r denotes 0 to 3Z denotes oxygenW denotes hydroxylR.sup.1 denotes --NH--C(.dbd.NH)--NH.sub.2R, R.sup.2, R.sup.3 denote hydrogenR.sup.4 denotes --CO--NHR.sup.5,where --NH--R.sup.5 represents an .alpha.-amino acid radical, have useful pharmacological properties such as inhibition of platelet aggregation and osteoclast binding to the bone surfaces.Type: GrantFiled: July 22, 1993Date of Patent: June 13, 1995Assignee: Cassella AGInventors: Gerhard Zoller, Bernd Jablonka, Melitta Just, Otmar Klingler, Gerhard Breipohl, Jochen Knolle, Wolfgang Konig